Become an IMR Panelist
IMR Logo

Interstitial Lung Disease Market Comprehensive Analysis & Growth Outlook to 2032

Interstitial Lung Disease Market by Disease Type (Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis), Drug Type (Corticosteroids, Anti-fibrotic Medication, Pirfenidone, Nintedanib), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region

  • Report ID : 20132
  • Category : Pharmaceutical and Healthcare
  • Format :Excel formatPDF formatWord format
Request Sample

Interstitial Lung Disease Market Synopsis:

Interstitial Lung Disease Market Size Was Valued at USD 1.8 Billion in 2023, and is Projected to Reach USD 3.2 Billion by 2032, Growing at a CAGR of 6.6% From 2024-2032.

Interstitial Lung Disease (ILD) are diseases that affect the interstitium, the tissue and the space surrounding alveoles of the lungs. ILD is a disease that causes the gradual build-up of scar tissue in the lungs making it difficult for the lungs to deliver oxygen to the bloodstream. This disease can be attributed to humoral factors, the effects of the environment, hereditary factors, autoimmune diseases and infections. This condition results in shortness of breath, coughing that does not cease, fatigue and in critical cases respiratory complications. Although Intersitial Lung Disease could be defined as different diseases such as IPF, sarcoidosis, and hypersensitivity pneumonitis, its classification cannot be simplified and thus can be considered a critical diagnosis. Since the path of this disease leads to inevitable changes in the lungs, it is essential to detect it in the early stages.

The market for Interstitial Lung Disease is rapidly expanding because of the increased prevalence of ILD across the world, increasing elderly population, and raising disease awareness. Specifically, one type of ILD called idiopathic pulmonary fibrosis (IPF), is becoming more common and will require more effective treatments. It is also advancing through the development of technologies through which ILD may be diagnosed early including high resolution CT scans and genetic profiling. Moreover, novel therapeutic agents, the progression of biologics and Targeted therapy that work toward probing the fibrosis seemed to have heightened interest in the market. These therapies have met clinical trial safety and efficacy and are anticipated to transform the face of ILD treatment.

Pharmaceutical companies’ rising rate of research and development to find new therapies for ILD is one of the factors bolstering the market growth. More potent drugs are being researched due to an increase in knowledge as to the etiology of ILD. In addition, the collaborations between the biotechnology firms and research universities are speeding up the development of drugs for ILD also for diseases such as IPF. Due to this there has been keen emphasis and interest in discovering more efficient treatment methods thus resulting in formation of competitive market environment, thus expected to grow throughout the forecast period. The demand for ILD treatment can further be supplemented with the more clinical trials, more approvals and relatively more brands of the drug approved for treating ILD than in the past.

Interstitial Lung Disease

Interstitial Lung Disease Market Trend Analysis:

Rise of Biologic Treatments

  • One phenomenal that was evident in the Interstitial Lung Disease market is the rising promise in biologic medications. These therapies are availed increasingly because the former kind works at molecular level where fibrosis and inflammation are initiated. As precision medicine is moving forward, the biologic agents which were initially developed to block certain proteins, enzymes or receptors in the pathophysiology of the disease are even being personalized. This is characterised by a rising approval of new biological agents such as monoclonal antibodies, growth factor inhibitors and other biologics that have demonstrated potential at clinical trials. Therefore, biologic drugs are expected to form a huge percentage of treatment method for ILD, as compared to corticosteroids and immunosuppressive drugs. These therapies offer much hope to the patients by halting the advance of this disease and enhance their lungs’ ability.

Growing Demand for Targeted Therapies

  • Furthermore, the growing demand for efficient therapeutic methods currently stands as a highly promisable opportunity in the Interstitial Lung Disease industry. This has spurred the need for effective drugs that can treat pathology at its source rather than just being able to reduce inflammation and fibrosis which have shown promising results. Additionally, when the disease increases in popularity around the world, it truly becomes a driver for research and development in the market. Scientists have also urged pharmaceutical firms to research on more effective combinations of drugs and bio drugs for treatment of various kinds of ILD. The opening for value creation is in creating treatment regimens that have more acceptable side effects and better therapeutic impact on the patient. Furthermore, with the increase of targeted therapies, treatment with drugs based on the genetics of a patient can become new market leaders in the fight against ILD and a decrease in the incidence of the disease around the world.

Interstitial Lung Disease Market Segment Analysis:

Interstitial Lung Disease Market is Segmented on the basis of Disease Type, Drug Type, Distribution Channel, and Region

By Disease Type, Interstitial Pneumonia segment is expected to dominate the market during the forecast period

  • The Interstitial Pneumonia segment holds the largest market share in the Interstitial Lung Disease market throughout the forecast period. This population comprises diseases like the idiopathic pulmonary fibrosis that fall under the most severe category of the ILD. Interstitial Pneumonia cause fibrosis of lung tissues, consequently affects the breathing and leads to low levels of oxygen in the blood. That is why the subsequent treatment for the diseases such as IPF is searched mostly due to high mortality rates for such conditions. Similarly, the necessity of therapies for Interstitial Pneumonia is assumed to be the highest among the existing types of ILD, which will provide a boost to the market.

By Drug Type, Corticosteroids segment expected to held the largest share

  • The Corticosteroids segment is anticipated to capture the largest share in the Interstitial Lung Disease market, due to the fact that these medicines are commonly used in controlling inflammation and fibrosis in ILD patients. Systemic corticosteroids are the most common drugs used to manage initial treatment of ILD because of their capacity to suppress inflammation and immunological response. However, serious side effects of long-term corticosteroid use including weight gain and increased susceptibility to infections have not dampened the use of corticosteroids in the management of ILD patients. The corticosteroids, particularly the orally inhaled products, capture a large market share because they are very effective, fairly inexpensive, and administered easily.

Interstitial Lung Disease Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

  • It is predicted that North America will occupy a very large share in the entire Interstitial Lung Disease market, globally, by the year 2023. The region’s protruding standing in this project can be explained by raised figures in the occurrence of ILD, particularly IPF alongside availability of good health care facilities. Also, the United States, based on research and development investments, drug approvals, and new therapy introduction remains an unswerving leader in this market. It is estimated that North America has the largest share of the market, Availability of technological support, high levels of investments in the development of healthcare services and infrastructure, early diagnosis, and treatment also contribute to the market’s growth in the examined region.

Active Key Players in the Interstitial Lung Disease Market

  • AbbVie (USA)

  • Actelion Pharmaceuticals (Switzerland)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb (USA)
  • Cipla Limited (India)
  • Galapagos NV (Belgium)
  • Gilead Sciences, Inc. (USA)
  • GlaxoSmithKline (UK)
  • InterMune (USA)
  • Merck & Co., Inc. (USA)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (USA)
  • Roche Holding AG (Switzerland)
  • Sanofi (France)
  • Teva Pharmaceuticals (Israel)
  • Other Active Players.

Global Interstitial Lung Disease Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 1.8 Billion

Forecast Period 2024-32 CAGR:

 6.6%

Market Size in 2032:

USD 3.2 Billion

Segments Covered:

By Disease Type
  • Interstitial Pneumonia
  • Idiopathic Pulmonary Fibrosis
  • Nonspecific Interstitial Pneumonitis
  • Hypersensitivity Pneumonitis
  • Cryptogenic Organizing Pneumonia (COP)
  • Sarcoidosis
  • Acute Interstitial Pneumonitis

By Drug Type
  • Corticosteroids
  • Anti-fibrotic Medication
  • Pirfenidone
  • Nintedanib

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies 

By Region
  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC)
  • Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:
  • Increasing prevalence of ILD

Key Market Restraints:
  • The high cost of treatment

Key Opportunities:
  • The development of targeted therapies and biologics

Companies Covered in the report:
  • AbbVie (USA), Actelion Pharmaceuticals (Switzerland), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA) and Other Active Players.

Frequently Asked Questions :

What would be the forecast period in the Interstitial Lung Disease Market research report?
The forecast period in the Interstitial Lung Disease Market research report is 2024-2032.
Who are the key players in the Interstitial Lung Disease Market?
AbbVie (USA), Actelion Pharmaceuticals (Switzerland), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA), Cipla Limited (India), Galapagos NV (Belgium), Gilead Sciences, Inc. (USA), GlaxoSmithKline (UK), InterMune (USA), Merck & Co., Inc. (USA), Novartis International AG (Switzerland), Pfizer Inc. (USA), Roche Holding AG (Switzerland), Sanofi (France), Teva Pharmaceuticals (Israel), Other Active Players.
What are the segments of the Interstitial Lung Disease Market?
The Interstitial Lung Disease Market is segmented into Disease Type, Drug Type, Distribution Channel and region. By Disease Type, the market is categorized into Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis. By Drug Type, the market is categorized into Corticosteroids, Anti-fibrotic Medication, Pirfenidone, Nintedanib. By Distribution Channel, the market is categorized into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Russia, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
What is the Interstitial Lung Disease Market?
Interstitial Lung Disease (ILD) are diseases that affect the interstitium, the tissue and the space surrounding alveoles of the lungs. ILD is a disease that causes the gradual build up of scar tissue in the lungs making it difficult for the lungs to deliver oxygen to the bloodstream. This disease can be attributed to humoral factors, the effects of the environment, hereditary factors, autoimmune diseases and infections. This condition results in shortness of breath, coughing that does not cease, fatigue and in critical cases respiratory complications. Although Intersitial Lung Disease could be defined as different diseases such as IPF, sarcoidosis, and hypersensitivity pneumonitis, its classification cannot be simplified and thus can be considered a critical diagnosis. Since the path of this disease leads to inevitable changes in the lungs, it is essential to detect it in the early stages.
How big is the Interstitial Lung Disease Market?
Interstitial Lung Disease Market Size Was Valued at USD 1.8 Billion in 2023, and is Projected to Reach USD 3.2 Billion by 2032, Growing at a CAGR of 6.6% From 2024-2032.
Request Sample

Related Reports

Services Designed to Meet Your Priorities

Understand your customers' needs so can deliver better services and experiences.

Show more

Subscribe to our Newsletter

Stay in touch with us to get latest news and discount coupons.